Alkermes(ALKS)
Alkermes plc is a pharmaceutical company that focuses on central nervous system (CNS) diseases like schizophrenia, bipolar disorder, depression, addiction and multiple sclerosis. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Aristada | Aripiprazole lauroxil | 2015-10-05 | 2030-2039 | |
| Isosorbide | Isosorbide | 1998-09-22 | ||
| Ketoprofen | Ketoprofen | 1997-12-10 | ||
| Lybalvi | Olanzapine, Samidorphan l-malate | 2021-05-28 | 2025-2041 | |
| Vivitrol | Naltrexone | 2006-04-13 | 2024-2034 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use